share_log

UBS Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $85

Benzinga ·  May 8 09:14

UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to $85.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment